Novo Nordisk Hits Record High After Study Finds Obesity Drug Wegovy Cuts Heart Risk

Novo Nordisk Hits Record High After Study Finds Obesity Drug Wegovy Cuts Heart Risk Novo Nordisk shares in Copenhagen jumped to a record high on Tuesday after headline results from the SELECT cardiovascular outcomes trial showed obesity drug Wegovy reduces cardiovascular events and helps with weight loss. "The double-blinded trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular events (MACEs) over a period of up to five years," Novo Nordisk wrote in a statement. The statement continued,...